Aligning global value-based decision making

THE CIRS 2020 AGENDA

CONSENSUS • TRUST • ACCESS
MISSION

To maintain a leadership role in identifying and applying scientific principles for the purpose of advancing regulatory and health technology assessment (HTA) policies and processes in developing and facilitating access to medicinal products

KEY ACTIVITIES

International Workshops: Meetings for members are convened at which invited participant interactions are optimised to facilitate networking, constructive discussion, recommendations and actions.

CIRS Research Projects: Specialised research and surveys are carried out among leading pharmaceutical companies and regulatory and HTA agencies with expert analyses and interpretation of the findings.

Identification of and Advocacy for International Best Practices: Using findings from our Workshops and research projects CIRS interacts with companies, regulators, HTA agencies and other international organisations to promulgate efficiencies in global medicine development.

Publications and Presentations: Reports are prepared from Workshops and projects. Dissemination of findings and recommendations through the R&D Briefing series, conference presentations, papers in peer-reviewed journals and the CIRS website are key aspects of the CIRS educational communication mission.

CIRS: VALUE, IMPACT, RETURN

For over 25 years, the Centre for Innovation in Regulatory Science (CIRS) has provided a neutral forum for the evolution of the concepts, methodologies and policies that improve the effectiveness, efficiency and decision making of stakeholders in the development of and access to safe and effective medicines.

How does CIRS provide value?

- Facilitating interaction among stakeholders
- Evolving best practices
- Offering decision-making tools
- Providing data and analyses to inform policy decisions

- Demonstrating the relevant application of metrics
- Strengthening agency capacity
- Aligning regulatory and HTA needs
- Recording and communicating situational analyses

CIRS Workshops provide exceptional learning and networking opportunities where participants can interact with peers in an atmosphere of informed and productive discussion to produce recommendations to move important topics forward in the development, regulation and reimbursement of medicines.

CIRS Workshops: impact and return on investment

- Strategic policy-level direction
- Challenge to current thinking
- Platform for improved decision making

- Thought leadership
- Senior-level insights
- Safe-harbour discussions
- Contextual reflections

- Translational change
- Hypothesis generation and testing
- Multiple perspectives

- Relationship building
- International engagement
- Network of influences

- Collaborative engagement
- Shared and enlarged resources
2020 WORKSHOPS

11-12 June, Tyson’s Corner, Virginia, USA
Digital Health: Exploring the Regulatory and HTA Landscape – How are Companies and Agencies Leveraging AI and Digital Technology to Improve Decision Making?

OBJECTIVES
- Discuss how agencies and companies are currently developing the role of digital technology in the development, review and reimbursement of medicines
- Identify how to best manage the uncertainty as to how agencies will respond to the growing use of innovative digital technology
- Recommend areas of work that could allow digital health to maximise its potential within a fit for purpose regulatory and HTA environment

Key discussion points:
- How digitisation and digital health technologies are transforming healthcare and how companies, regulatory and HTA agencies are looking to derive actionable insights from its utilisation?
- What are the opportunities to shape the environment both pre- and post-approval so as to reduce potential barriers going forward?

15-16 September, Bogota, Colombia
Effectiveness of the Regulatory Approval Process – Moving from Measuring Performance to Operational Excellence

OBJECTIVES
- Discuss what is required beyond measuring just time to understand a regulatory authority’s performance and how this can be utilised by agencies to improve their effectiveness
- Identify comparative measures of effectiveness that could allow for cross agency learning
- Make recommendations on a common set of key indicators across authorities that could be used as a measure of effectiveness

Key discussion points:
- Having an effective regulatory approval process: why is it important and what does this mean to stakeholders?
- Quality of Dossier submission - how does this influence the effectiveness of the review and what can be done to ensure quality?

30 September - 1 October, Runnymede Hotel, Surrey, UK
Regulatory and HTA Interactions in the Development Space – Is this Enabling Better Evidence Generation, Improved Probability of Success and Patient Access?

OBJECTIVES
- Discuss the current and future of role regulatory/HTA and HTA/HTA initiatives for interactions within and across jurisdictions
- Identify through case studies the key areas and types of interactions between stakeholders which are seen as effective models
- Understand the value they bring to enabling improved decision making by stakeholders and what can be learnt across jurisdictions

Key discussion points:
- How the level and depth of interactions between agencies is changing and the future direction of travel for such interactions?
- What are the key areas where there are divergences in evidence needs and which interactions are of value to improve decision making?
THE CIRS REGULATORY AND ACCESS PROGRAMME

Following advice from the Scientific Advisory Board (SAC), CIRS activities in the regulatory and access arenas were fully aligned in 2019. Because of CIRS’s special ability to coordinate the input and activities of multiple stakeholders from a global perspective, the “Regulatory and Access Programme” addresses our activities in this holistic manner. The HTA Steering Committee advises CIRS on HTA-specific activities related to the Programme.

DRIVING THEMES

**METRICS**
Managing uncertainty and improving predictability

**QUALITY OF PROCESS**
Improving development and regulatory processes and ultimately, the quality of decision making

**ALIGNMENT**
Promoting convergence within and across organisations and stakeholders
<table>
<thead>
<tr>
<th>GLOBAL DEVELOPMENT PROGRAMME TRACK</th>
<th>HTA TRACK</th>
<th>COMBINED “REGULATORY AND ACCESS PROGRAMME”</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 paid registrations per Workshop (3 Workshops)</td>
<td>1 paid registration per Workshop (3 Workshops)</td>
<td>Two paid registrations per Workshop (3 Workshops per year)</td>
</tr>
<tr>
<td>Global Development (regulatory focused) Technical Forum (annual)</td>
<td></td>
<td>Regulatory-focussed Technical Forum (annual) registration fee included (accommodation not included)</td>
</tr>
<tr>
<td>Regulatory advocacy with ICH+ countries</td>
<td>European, Canadian and US HTA advocacy</td>
<td>Aligned regulatory and access advocacy with ICH+ countries</td>
</tr>
<tr>
<td>HTA focussed Technical Forum (annual)</td>
<td>HTA/HEOR-focussed Technical Forum (annual) - registration fee included (accommodation not included)</td>
<td></td>
</tr>
<tr>
<td>Targeted international regulatory advocacy</td>
<td>Advocacy with access agencies in the global environment</td>
<td>Aligned global international advocacy across regulatory and access agencies</td>
</tr>
<tr>
<td>Support for the Annual Regulator’s Forum</td>
<td></td>
<td>Support for the Annual Regulator’s Forum; ad hoc Agency Discussion Meetings; new periodic HTA agency webinars</td>
</tr>
<tr>
<td>Focus Study participation</td>
<td>Focus Study participation</td>
<td>Focus Study participation across regulatory and access topics</td>
</tr>
<tr>
<td>Regulatory agency performance metrics benchmarking</td>
<td></td>
<td>Regulatory agency performance metrics benchmarking; HTADock integrated regulatory and HTA database outcomes analyses</td>
</tr>
</tbody>
</table>
| Key regulatory projects: benefit-risk, International Summary Approach to Benefit Risk Evaluation (iSABRE), PhD student support | Key HTA projects: Factors influencing HTA recommendations in Europe; Exploring Approaches to HEOR/HTA decision making; Commonality in evidentiary requirement across regulatory and HTA stakeholders | Key aligned projects  
- Regulatory: iSABRE  
- Quality Scorecards/Decision Making activities; Facilitated regulatory and access pathways; Commonality in evidentiary requirement across regulatory and HTA stakeholders  
- PhD student support - regulatory and HTA thesis themes |
CIRS ACTIVITIES 2018-2020

RESEARCH THEMES
The Centre for Innovation in Regulatory Science addresses a wide range of topics related to the development, regulatory review and reimbursement of medicines. The driving themes for the rolling three-year programme 2018-2020 have been as follows:

• Enabling Innovation and Upstream Partnering to Enhance Downstream Innovation
• Pragmatic Approaches to Transparent Decisions: Reliance, Recognition, Reciprocity and Regionalisation
• Patient Engagement and “Centricity”
• Disruptive Technologies: The Impact of Digital and Other Technologies on Development, Regulation and Value

ACHIEVEMENTS FOR 2018-2019
CIRS has been disseminating its research outputs and tools through a number of channels:

- 9 Research and Development Briefings to disseminate high level findings from original research and to address important policy changes, for example: regulatory review process approvals by global regulatory agencies, the review of HTA outcomes as well as the sequence of regulatory and HTA processes
- 12 Publications in Peer-Reviewed Journals by CIRS staff as well as a result of collaborations with PhD students whose studies are jointly supervised by CIRS and Utrecht University or University of Hertfordshire
- 6 International Workshops organised by CIRS with participants from 50+ organisations from across academia, regulatory and HTA agencies as well as patient groups, with actionable recommendations developed from each meeting
- 18 Poster and Podium Presentation at major regulatory and HTA Conferences and Fora
- 35+ visits with senior staff from regulatory authorities and HTA/Payer bodies in Europe, USA, Africa, Asia, Latin America and the Middle East in order to identify current practice and to promote the use of CIRS tools and international best practice

CIRS publications, briefings and workshop reports can be viewed at www.cirsci.org

WHAT OUR STAKEHOLDERS SAY
“CIRS Workshops provide an excellent opportunity to meet top management from EMA and FDA. Good open discussion between stakeholders that I have not experienced before.” Pharmaceutical company

“CIRS Research and Development Briefings provide very useful information as we have to account for our timelines to our principals in the face of shortages of critical medicines. The snippets of ideas on how other resource limited agencies managed to work smarter will help us use our meagre resources strategically and efficiently.” Regulatory agency

“The overall quality of discussions at CIRS Workshops is excellent, the engagement with and by the HTA/payer community is impressive and sets a nice course forward” HTA agency
ONGOING PROJECTS AND ACTIVITIES FOR 2020

As part of our aligned Regulatory and Access Programme, CIRS will continue with the following research activities in 2020:

REGULATORY RESEARCH PROGRAMMES

<table>
<thead>
<tr>
<th>Performance Metrics in Mature and Emerging Countries: Embedding measurement</th>
<th>Quality - Good Review/Submission Practices: Establishing and adhering to them</th>
<th>Benefit Risk: Incorporating systematic structured approach</th>
<th>Facilitated Regulatory Pathways (FRPs) and Reliance Routes: Adding value to the review system</th>
</tr>
</thead>
</table>

Building Quality into Decision Making Practices

HTA RESEARCH PROGRAMMES

<table>
<thead>
<tr>
<th>Mapping of Regulatory &amp; Reimbursement Systems + process archetypes</th>
<th>Performance metrics: HTA agency benchmarking</th>
<th>HTA/Reg interaction: Alignment in evidence requirements, FRPs</th>
<th>Stakeholder involvement: Early scientific advice, Patient involvement</th>
</tr>
</thead>
</table>

SPECIAL PROJECTS

CIRS’ status as a trusted resource as well as its extensive experience has been recognised by organisations through the commissioning of Special Projects. Examples of collaborating organisations include the ICH, WHO, Gates Foundation, PhRMA and Centres of Excellence as well as member companies and agencies. CIRS welcomes suggestions and ideas for future projects.

PLANNING BEYOND 2020

A rolling, three-year programme of discussion topics will be maintained in consultation with the CIRS SAC and HTA Steering Committee as well as member companies and agencies. The aim will be to allow rapidly developing issues to be included on the 2021-2023 research agenda in addition to the major ongoing CIRS research projects. Proposed agenda topics from the SAC are outlined below, but we always welcome suggestions as long as they are within the scope of our mission and objectives.

- Bringing the patient viewpoint into the decision-making process
  Measuring the impact of patient involvement in review and reimbursement
- Acceptance of a collaborative/work sharing environment
  Building trust across regions and between agencies
- Convergence of technologies and its impact on regulation
  For example, complex combination therapies, digital health, historical controls
- Improving predictability of regulatory and HTA outcomes
  Alignment of patient, regulatory and HTA priorities to expedite access to medicines
- Regionalisation is key
  The importance of reliance models, work sharing approaches and regionalisation to support availability of new medicines globally
- Change culture to accept new types of endpoints
  Translating real-world evidence/data into regulatory-grade evidence

Patients

Aligned priorities

Trust

Globalisation

New technologies

Real World Evidence
## Member Companies and Participating Authorities

### Member Companies

<table>
<thead>
<tr>
<th>Country</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>Abbot</td>
</tr>
<tr>
<td>Europe</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Japan</td>
<td>Astellas</td>
</tr>
<tr>
<td>Brazil</td>
<td>Amgen</td>
</tr>
<tr>
<td>Canada</td>
<td>Bayer</td>
</tr>
<tr>
<td>Chile</td>
<td>Biogen</td>
</tr>
<tr>
<td>Columbia</td>
<td>Eli Lilly and Co.</td>
</tr>
<tr>
<td>Denmark</td>
<td>Johnson &amp; Johnson</td>
</tr>
<tr>
<td>Norway</td>
<td>Merck &amp; Co</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Sweden</td>
<td>Vertex</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Sanofi</td>
</tr>
<tr>
<td>United States</td>
<td>UCB</td>
</tr>
</tbody>
</table>

### Participating Regulatory Authorities

<table>
<thead>
<tr>
<th>Country</th>
<th>Authority</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>ANMAT</td>
</tr>
<tr>
<td>Brazil</td>
<td>ANVISA</td>
</tr>
<tr>
<td>Canada</td>
<td>Health Canada</td>
</tr>
<tr>
<td>Chile</td>
<td>ANAMED</td>
</tr>
<tr>
<td>Colombia</td>
<td>INVIMA</td>
</tr>
<tr>
<td>Cuba</td>
<td>CECMED</td>
</tr>
<tr>
<td>Mexico</td>
<td>COFEPRIS</td>
</tr>
<tr>
<td>Peru</td>
<td>DIGEMID</td>
</tr>
<tr>
<td>United States</td>
<td>FDA</td>
</tr>
<tr>
<td>Regional initiatives</td>
<td>CARICOM-CRS/PAHO</td>
</tr>
</tbody>
</table>

### HTA and Coverage Bodies

<table>
<thead>
<tr>
<th>Country</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>PBAC</td>
</tr>
<tr>
<td>Belgium</td>
<td>INAMI; KCE</td>
</tr>
<tr>
<td>Brazil</td>
<td>CONITEC</td>
</tr>
<tr>
<td>Canada</td>
<td>CADTH; DSEN, Canadian Institutes of Health Research, INESSS, Alberta Health Services</td>
</tr>
<tr>
<td>Croatia</td>
<td>AAZ</td>
</tr>
<tr>
<td>Denmark</td>
<td>Danish Health and Medicines Authority</td>
</tr>
<tr>
<td>England</td>
<td>NICE</td>
</tr>
<tr>
<td>Europe</td>
<td>EUenetHTA</td>
</tr>
<tr>
<td>Finland</td>
<td>THL</td>
</tr>
<tr>
<td>France</td>
<td>HAS</td>
</tr>
<tr>
<td>Germany</td>
<td>G-BA, AOK-Bundesverband</td>
</tr>
<tr>
<td>Italy</td>
<td>AIFA</td>
</tr>
<tr>
<td>Lithuania</td>
<td>VASPVT</td>
</tr>
<tr>
<td>Norway</td>
<td>NOKC</td>
</tr>
<tr>
<td>Poland</td>
<td>AHTAPol</td>
</tr>
<tr>
<td>Portugal</td>
<td>INFARMED</td>
</tr>
<tr>
<td>Scotland</td>
<td>Scottish Medicines Consortium</td>
</tr>
<tr>
<td>Singapore</td>
<td>ACE</td>
</tr>
<tr>
<td>Spain</td>
<td>CAHIAQ, Osteba</td>
</tr>
<tr>
<td>Sweden</td>
<td>TLV</td>
</tr>
<tr>
<td>Switzerland</td>
<td>BAG</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>ZIN</td>
</tr>
<tr>
<td>United States</td>
<td>UnitedHealth Group; TEC, Blue Cross/Blue Shield Association; Kaiser Permanente Institute for Health Policy; AHRQ; OPTUM</td>
</tr>
</tbody>
</table>

### EMEA - Country and Authority

<table>
<thead>
<tr>
<th>Country</th>
<th>Authority</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denmark</td>
<td>Danish Health and Medicines Authority</td>
</tr>
<tr>
<td>EU</td>
<td>EMA</td>
</tr>
<tr>
<td>Ghana</td>
<td>FDA Ghana</td>
</tr>
<tr>
<td>Ireland</td>
<td>HPRA</td>
</tr>
<tr>
<td>Israel</td>
<td>MoH</td>
</tr>
<tr>
<td>Jordan</td>
<td>JFDA</td>
</tr>
<tr>
<td>Kuwait</td>
<td>KDFC</td>
</tr>
<tr>
<td>Oman</td>
<td>MoH</td>
</tr>
<tr>
<td>Qatar</td>
<td>SCH</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>SFDA</td>
</tr>
<tr>
<td>South Africa</td>
<td>SAHPRA</td>
</tr>
<tr>
<td>Sweden</td>
<td>MPA</td>
</tr>
<tr>
<td>Switzerland</td>
<td>Swissmedic</td>
</tr>
<tr>
<td>Turkey</td>
<td>TITCK</td>
</tr>
<tr>
<td>United Arab Emirates</td>
<td>MoH</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>MHRA</td>
</tr>
<tr>
<td>Regional initiatives</td>
<td>GHC, AMRH-EAC, Zazibona/ SADC, WAHO</td>
</tr>
</tbody>
</table>

### Asia - Country and Authority

<table>
<thead>
<tr>
<th>Country</th>
<th>Authority</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>TGA</td>
</tr>
<tr>
<td>China</td>
<td>NMPA</td>
</tr>
<tr>
<td>Chinese Taipei</td>
<td>TFDA; CDE</td>
</tr>
<tr>
<td>Indonesia</td>
<td>NAFDC</td>
</tr>
<tr>
<td>Japan</td>
<td>MHJW, PMDA</td>
</tr>
<tr>
<td>Malaysia</td>
<td>NPRA</td>
</tr>
<tr>
<td>Philippines</td>
<td>PFDA</td>
</tr>
<tr>
<td>Singapore</td>
<td>HSA</td>
</tr>
<tr>
<td>South Korea</td>
<td>MFDS</td>
</tr>
<tr>
<td>Thailand</td>
<td>Thai FDA</td>
</tr>
<tr>
<td>Vietnam</td>
<td>DAV</td>
</tr>
<tr>
<td>Regional initiatives</td>
<td>APEC</td>
</tr>
</tbody>
</table>
Scientific Advisory Council
Chair: Adjunct Prof John Skerritt, Deputy Secretary for Health Products Regulation, Department of Health, Canberra, Australia
Vice-Chair: TBA

Dr Claus Bolte, Head of Sector Marketing Authorisation, Swissmedic
Prof Hans-Georg Eichler, Senior Medical Officer, EMA
Dr Harald Enzmann, Chair, CHMP/EMA
Dr Ian Hudson, Senior Advisor, Integrated Development, Global Health, Bill and Melinda Gates Foundation, UK
Prof John Lim, Professor of Practice, Executive Director of CoRE, Duke-NUS Medical School and Policy Lead, SingHealth Duke-NUS Global Health Institute
Dr Teresa Mullin, Director, Office of Strategic Programs at US FDA, CDER
Dr Brian O’Rourke, CEO and President, CADTH, Canada
Dr Junko Sato, Office Director, Office of International Program, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Dr Xie Songmei, Deputy Director of Clinical Department Center for Drug Evaluation, NMPA, China
Dr John Patrick Stewart, Director General, Therapeutic Products Directorate, Health Canada
Deborah Autor, Global Head of Regulatory Excellence, AstraZeneca, USA
Dr Fabio Bisordi, Global Head International Regulatory Policy, F.Hoffmann-La Roche Ltd
Dr Tim Garnett, CMO, SVP, Eli Lilly
Dr Ian Hudson, Senior Advisor, Integrated Development, Global Health, Bill and Melinda Gates Foundation, UK
Dr John Lim, Professor of Practice, Executive Director of CoRE, Duke-NUS Medical School and Policy Lead, SingHealth Duke-NUS Global Health Institute

Dr Fabio Bisordi, Global Head International Regulatory Policy, F.Hoffmann-La Roche Ltd
Dr Tim Garnett, CMO, SVP, Eli Lilly
Adrian Griffin, Vice President for HTA Policy, Johnson & Johnson
Dr Peter Honig, Senior Vice President and Head of Worldwide Safety and Regulatory, Pfizer
Mark Hope, Senior Vice President, Global Regulatory Head, UCB
Dr David Jefferys, SVP, Head of Global Regulatory, Eisai Europe Ltd
Dr Sabine Luik, Chief Regulatory Officer, SVP, Global Regulatory Affairs and Quality Assurance, GlaxoSmithKline
Dr Roopal Thakar, Vice President, Global Regulatory Affairs, Abbvie
Max Wegner, Head Regulatory Affairs PH & CH, Bayer AG

Specialist Advisors to the Executive Director
Dr Thomas Lönngren, Former Executive Director, EMA
Dr Murray Lumpkin, Deputy Director, Integrated Development, and Lead for Global Regulatory Systems Initiatives, Bill and Melinda Gates Foundation
Prof Mamoru Narukawa, Associate Professor Pharmaceutical Medicine, Kitasato University Graduate School of Pharmaceutical Sciences, Tokyo, Japan
Dr Tomas Salmonson, Former Chair, CHMP/EMA
Dr Joseph Scheeren, President, CEO, Critical Path Institute

HTA Steering committee
Chair: Dr Brian O’Rourke, CEO and President, CADTH, Canada
Vice-Chairman: Prof Adrian Towe, Director Emeritus and Senior Research Fellow, OHE

Dr Nick Crabb, Programme Director, Scientific Affairs, NICE
Prof Hans-Georg Eichler, Senior Medical Officer, EMA
Wim Goettsch, Associate Professor HTA, Utrecht University; Special advisor HTA, ZIN
Evert Jan van Lente, Director EU-Affairs, AOK-Bundesverband
Niklas Hedberg, Chief Pharmacist, TLV
Andrew Mitchell, Strategic Adviser, DoHA

Adrian Griffin, Vice President for HTA Policy Johnson & Johnson
Dr Michael Happich, Director, BioMed HTA , Eli Lilly and Co
Dr Adam Heathfield, Senior Director, Patient and Health Impact Innovation Centre, Pfizer
Dr Maria Kubin, Head of MACS TA Cardiovascular, Bayer
Dr Vanessa Elisabeth Schaub, Global Access Senior Health Systems Strategy Leader HTA & Reimbursement, Roche
Dr Sean Tunis, Senior strategic advisor, Centre for Medical Technology Policy

Prof Finn Børlum Kristensen, Former EUnetHTA Executive Committee Chairman and EUnetHTA Secretariat Director, Faculty of Health Sciences, University of Southern Denmark

Dr Jamie Munro, Executive Director, CIRS
Dr Lawrence Liberti, Head Regulatory collaboration, CIRS
Dr Neil McAuslane, Scientific Director, CIRS
Tina Wang, Manager, HTA Programme, CIRS
CIRS develops tools to facilitate decision making within companies, regulatory and HTA agencies, with the overarching aim to increase transparency of processes, support quality decision making and provide global advocacy in support of regulatory and HTA strengthening. CIRS tools are used in special projects with individual companies and agencies but are also available for an organisation's own use.

**Navigating pathways**

The **CIRS Regulatory and Reimbursement Atlas™** maps interactions between regulators, HTA agencies and payers across 56 jurisdictions, helping organisations to navigate the increasingly complicated regulatory and reimbursement landscape.

Find out more by visiting: www.cirs-atlas.org (Free for CIRS members)

**Assessing quality of decision making**

CIRS has developed **10 Quality Decision-Making Practices** to help organisations monitor decision-making processes, improve awareness about best practice and reduce uncertainty.

Implementation of these practices is assessed using the **Quality of Decision-Making Orientation Scheme (QoDoS©)**. Find out more in CIRS R&D Briefing 61.

**Regulatory scorecards**

The **CIRS Quality Scorecard** is an internationally accepted scorecard system for monitoring the quality of regulatory submission (completed by agencies) and their review (completed by companies).

Find out more by visiting: www.cirsci.org/global-development-track/quality-decision-making

**Benefit risk decisions**

**UMBRA** is a universal framework bringing together methodologies for benefit risk.

It includes two tools:

- **CIRS-BRAT**, for visualising and assessing benefit risk. Download at: www.cirs-brat.org
- **iSABRE**, which documents benefit risk through a summary template. Find out more at: www.cirsci.org/global-development-track/isabre
Membership to the Regulatory and Access Programme is open to all pharmaceutical companies, in particular those engaged in research and development of new active substances, prescription medicines, devices and biologics with a view to global product development, regulatory affairs and market access.

The benefits enjoyed by members of CIRS include:

- Be part of the small interactive CIRS Workshops, which provide exceptional learning and networking opportunities where you can interact with peers from industry, regulatory authorities, HTA agencies and academia in an atmosphere of informed and productive discussion
- Full registration and accommodation (excluding travel) for two participants at each Workshop
- The opportunity to meet and network with senior regulatory personnel from government agencies, international pharmaceutical companies and academia
- The ability to contribute to the direction of the programme of work for CIRS and put forward subjects for discussion and debate at future Workshops as well as topics for surveys and studies
- The opportunity to be nominated for participation in the Advisory Management Committee or the Scientific Advisory Council, Steering Committees and Taskforces
- Exclusive, priority access to
  - Information derived from studies and surveys to which your organisation has contributed
  - Reports and slide presentations from CIRS Workshops
- Early access to
  - Reports and supportive documents from all Workshops and projects, projects highlighting regulatory and HTA developments, issues and attitudes as a unique information resource
  - Archives of all CIRS publications including survey and Workshop reports and R&D Briefings

The fee for the 2020 Regulatory and Access Programme entitles member organisations to all of the benefits of membership described in this brochure; this includes the full registration and accommodation (excluding travel) for two participants at each Workshop and registration for one person to each of the annual Forums. Additional participants may attend Workshops (space permitting) and will be assessed a registration fee (£950 per person per Workshop plus VAT where applicable), to cover direct participation costs (conference rate, meals and accommodations, administration and overhead; travel excluded).
The Centre for Innovation in Regulatory Science (CIRS) is a neutral, independently managed UK-based subsidiary company, forming part of the Clarivate Analytics group. CIRS’ mission is to maintain a leadership role in identifying and applying scientific principles for the purpose of advancing regulatory and HTA policies and processes. CIRS provides an international forum for industry, regulators, HTA and other healthcare stakeholders to meet, debate and develop regulatory and reimbursement policy through the innovative application of regulatory science and to facilitate access to medical products. This is CIRS’ purpose. CIRS is operated solely for promotion of its purpose. The organisation has its own dedicated management and advisory boards, and its funding is derived from membership dues, related activities, special projects and grants.

Centre for Innovation in Regulatory Science (CIRS)
Friars House, 160 Blackfriars Road, London SE1 8EZ, United Kingdom
Email: cirs@cirsci.org
Website: www.cirsci.org

www.linkedin.com/company/centre-for-innovation-in-regulatory-science-ltd/

Dr Jamie Munro, Executive Director
Dr Neil McAuslane, Director
Dr Lawrence Liberti, Head, Regulatory Collaborations
Dr Magda Bujar, Manager, Strategic Development
Dr Jesmine Cai, Senior Research Analyst
Dr Jenny Sharpe, Senior Scientific Writer
Gill Hepton, Administrator
Prisha Patel, Manager, Global Development Programme
Dr Céline Rodier, Senior Research Analyst
Ting Wang, Manager, HTA Programme
Prof Stuart Walker, Founder

jamie.munro@cirsci.org
nmcauslane@cirsci.org
lliberti@cirsci.org
mbujar@cirsci.org
jcai@cirsci.org
jsharpe@cirsci.org
ghepton@cirsci.org
ppatel@cirsci.org
crodier@cirsci.org
twang@cirsci.org
swalker@cirsci.org

Original artwork: Alan Chaston;
linesmandesign.co.uk